Corporate America evaluates the business impact of new weight loss drugs
[1/3]A 0.25 mg injection pen of Novo Nordisk’s weight loss drug Wegovy is shown in this September 1, 2023 photo illustration in Oslo, Norway. REUTERS/Victoria Klesty/Illustration/File Photo Get Licensing Rights Nov 8 (Reuters) – U.S. companies in sectors such as food and beverage makers and makers of glucose monitors are facing investor questions about future …
Corporate America evaluates the business impact of new weight loss drugs Read More »